Compare Realty Income Corp (O) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Realty Income Corp trades at $54.08 (market cap $51.26B), while State Street SPDR S&P Biotech ETF trades at $150.52 (market cap $10.11B). The key difference: Realty Income Corp is far larger — about 5.1× State Street SPDR S&P Biotech ETF's market cap, and Realty Income Corp pays a 6.01% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 127 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| O | XBI | |
|---|---|---|
Market Cap | $51.26B | $10.11B |
Volume | 12,300,266 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $67.56 | $169.55 |
52-Week Low | $53.35 | $104.99 |
Typical Hold Time | 127 Days | 37 Days |
Enterprise Value | $81.88B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $53.35, down 1.66% amid a bearish technical signal, with support at $52. The stock has missed EPS estimates for three consecutive quarters but maintains a 92.56% gross margin and 21.23% net income margin. Recent news highlights its 6% dividend yield and 136 consecutive dividend increases, though rising Treasury yields pressure REIT valuations.
The outlook is mixed: analyst consensus targets $64.80 (21% upside) with a 'Hold' bias, but debt-to-asset ratios have risen to 39.93% (2025). Key risks include interest rate sensitivity and earnings misses, while the dividend track record offers income stability. Investors face trade-offs between yield sustainability and fundamental headwinds.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
